

## **Treatment Options for Plaque Psoriasis: Effectiveness, Value, and Value-Based Price Benchmarks**

### ***Draft Background and Scope***

#### **Background**

Psoriasis is a common disease that causes red, scaly, raised lesions on the skin, most commonly on the elbows, knees, scalp, and back.<sup>1</sup> Psoriasis affects about 2% of the population and significantly decreases health-related quality of life, particularly if lesions are in areas that can affect daily functioning (e.g., the hands or soles of the feet) or affect social functioning (e.g., the face).<sup>2-4</sup> Psoriasis is a chronic inflammatory condition that is associated with systemic diseases including psoriatic arthritis, other autoimmune diseases, the metabolic syndrome, and cardiovascular disease.<sup>5</sup>

Cutaneous psoriasis types include plaque psoriasis, guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, inverse psoriasis, and nail psoriasis. Chronic plaque psoriasis accounts for about 80% to 90% of all patients with psoriasis. Up to 30% of patients with plaque psoriasis have at least some manifestations of psoriatic arthritis.<sup>6</sup>

Plaque psoriasis is caused by dysregulation of innate and adaptive immunity in genetically susceptible people.<sup>5</sup> This dysregulation produces an overabundance of inflammatory mediators such as tumor necrosis factor (TNF)-alpha and interleukins (IL)-12, 23, and 17A. Activated immune cells and inflammatory mediators lead to changes in and overgrowth of the surface layer of psoriatic skin.

Roughly 70% to 80% of patients with plaque psoriasis have mild disease that can be adequately managed with topical therapy. Definitions of “moderate-to-severe” plaque psoriasis vary, but generally consist of psoriasis that affects at least 5% of a patients’ body surface; produces lesions that have significant redness, thickness, and scale; or significantly reduces quality of life.<sup>7,8</sup>

Treatments for psoriasis can be grouped within 4 broad categories: 1) topical therapies such as steroids, vitamin D analogues, retinoids, and calcineurin inhibitors; 2) older systemic therapies, such as cyclosporine and methotrexate; 3) phototherapy such as psoralen and ultraviolet A radiation (PUVA); and 4) biologics or “targeted immunomodulators.” Clinical interest in this last category is high, as many patients with chronic plaque psoriasis do not see adequate or durable benefit from other systemic therapies or phototherapy. Additionally, targeted immunomodulators are associated with a high financial cost, some of which is passed on to patients. Targeted

immunomodulators approved for the treatment of moderate-to-severe plaque psoriasis in the United States consist of medications with activity against the following targets:

- **TNF:** adalimumab (Humira®), etanercept (Enbrel®), infliximab (Remicade®)
- **IL-17A:** secukinumab (Cosentyx®), ixekizumab (Taltz®), brodalumab (investigational)
- **IL-12/23:** ustekinumab (Stelara®)
- **Phosphodiesterase (PDE)-4:** apremilast (Otezla®) Although not technically a “biologic” apremilast is a novel, targeted, oral agent also approved for treatment of patients with moderate-to-severe psoriatic arthritis.

[Note: Certolizumab pegol (Cimzia®) and golimumab (Simponi®, Simponi ARIA) are anti-TNF agents that have been approved for the treatment of psoriatic arthritis, but not plaque psoriasis.]

Treatment of plaque psoriasis can be challenging for patients. It can be difficult to apply topical therapies, especially when the affected area involves the scalp or covers a large part of the body. Some therapies must be administered in a physician’s office, requiring patients and caregivers to take time off from work to get treatment. Insurance plans generally mandate “step therapy,” which requires patients and clinicians to first try a list of preferred medications and, only after repeated treatment failures, progress to non-preferred treatments.

Studies have found that up to half of patients are dissatisfied with psoriasis treatment.<sup>3,9</sup> Dissatisfaction may be due to the unpredictable effectiveness of agents, poor tolerability, lack of durable response, and lack of access to medications because of coverage restrictions or costs.<sup>3</sup> The newer targeted immunomodulators are generally more expensive than older medications and there are questions regarding how these costs align with the clinical value brought to patients.

## Report Aims

This project will evaluate both the comparative clinical effectiveness and value of targeted immunomodulators (biologics plus apremilast) for adults with moderate-to-severe plaque psoriasis. Note that, while many of these agents are FDA approved for the treatment of both plaque psoriasis and psoriatic arthritis, these conditions involve distinctly different sets of measures, outcomes, and clinical audiences. As such, our scope will be limited to the available evidence for plaque psoriasis, the more prevalent manifestation of the disease.

## Scope of the Evidence Review Focusing on Comparative Clinical Effectiveness


The proposed scope for this assessment is described below using the PICOTS (Population, Intervention, Comparators, Outcomes, Timing, and Settings) framework. Evidence will be collected from available randomized controlled trials as well as high-quality systematic reviews; higher-quality comparative cohort studies will also be evaluated as necessary. We will not restrict studies according to study duration or study setting; however, we will limit our review to those that capture the key outcomes of interest. We will supplement our review of published studies with data from conference proceedings, regulatory documents, information submitted by

manufacturers, and other grey literature when the evidence meets ICER standards (for more information, see <http://icer-review.org/wp-content/uploads/2016/02/Slides-on-value-framework-for-website-v4-13-16.pdf>).

## Analytic Framework

The general analytic framework for assessment of anti-plaque psoriasis medications is depicted in Figure 1 below.

**Figure 1. Analytic Framework: Management of Moderate-to-Severe Chronic Plaque Psoriasis**



PASI = psoriasis area severity index; PGA = physician global assessment

## Populations

The population of focus for this review is adults with moderate-to-severe chronic plaque psoriasis. Although not a focus of the review, we will not exclude patient populations with other concomitant psoriasis types or psoriatic arthritis, and will evaluate psoriasis outcomes in these subgroups if data are available.

## ***Interventions***

The interventions of interest are the targeted immunomodulators (biologics and apremilast) all but one of which have been approved for the treatment of moderate-to-severe plaque psoriasis:

- ***Anti-TNF agents:*** adalimumab, etanercept, infliximab
- ***Anti IL-17A agents:*** secukinumab, ixekizumab, brodalumab (not yet approved)
- ***Anti IL-12/13 agent:*** ustekinumab
- ***Anti-PDE4 agent:*** apremilast

## ***Comparators***

Wherever possible, we will evaluate head-to-head trials of these interventions. Other comparators may include placebo or other active treatments not listed above.

## ***Outcomes***

This review will examine key clinical outcomes, including outcomes common to plaque psoriasis trials. We will engage with patient groups and clinical experts to ascertain which outcomes are of greatest importance to patients and determine whether patient-reported outcomes or other evidence sources can be found to supplement the available clinical data. Initial discussions with patients, patient groups, clinicians, and publications from academic research groups indicate that people with psoriasis have symptoms and burdens that are not well-captured by standard clinical trial outcomes.<sup>3,10</sup>

### ***Clinical Trial and Study Outcomes***

- Psoriasis Area and Severity Index (PASI): 75, 90, 100
- Physician Global Assessment (PGA)
- Treatment-related adverse events

### ***Patient-Reported Outcomes***

- Dermatology Life Quality Index (DLQI)
- Other measures of health-related quality of life
- Symptom control
- Treatment tolerability

Evidence tables will be developed for each selected study and results will be summarized in a qualitative fashion; meta-analysis will be used to quantitatively summarize outcomes for the therapies of interest. In addition, we will consider network meta-analysis to combine direct and indirect evidence of effectiveness as available data permit.

## ***Timing***

Evidence on intervention effectiveness and harms will be derived from studies of any duration, although we are particularly interested in evidence of durability of response to medications, as well as long-term safety.

## **Settings**

Plaque psoriasis is generally treated in outpatient and/or clinic settings, which will be the focus of our review.

## **Simulation Models Focusing on Comparative Value**

As a complement to the evidence review, we will develop a simulation model to assess the cost-effectiveness of the regimens of interest. The model structure will be based in part on previously developed economic models assessing treatments for psoriasis and be conducted from a health system perspective over a lifetime time horizon.<sup>11</sup> The model will focus attention on regimens most likely to be used for adults with moderate-to-severe chronic plaque psoriasis who have failed topical and/or photo therapy.

Proposed regimens include:

- **Anti-TNF agents:** adalimumab, etanercept, infliximab
- **Anti IL-17A agents:** secukinumab, ixekizumab, brodalumab (not yet approved)
- **Anti IL-12/13 agent:** ustekinumab
- **Anti-PDE4 agent:** apremilast

Effectiveness will be estimated based on network meta-analyses of randomized controlled trials conducted in this patient population.

Key model outputs will include disease-specific measures such as the PASI, treatment-related adverse events, health-related quality of life, and systemic manifestations, as feasible. Costs will include those of current and subsequent treatment, management of adverse events, and ongoing care. Results will be expressed primarily in terms of the incremental cost per quality-adjusted life year (QALY) gained.

We will also assess the potential budgetary impact of each regimen over a 5-year time horizon, utilizing information on treatment costs and any cost offsets from reductions in use of other health care resources. Potential budgetary impact analyses will assume a product “uptake” rate over the 5-year period based on ICER criteria. Finally, we will develop a “value-based price benchmark” for each treatment reflecting prices aligned with long-term cost-effectiveness thresholds and below a threshold for potential budgetary impact that would exceed growth targets for national health care costs.

More information on ICER’s methods for estimating product uptake and calculating value-based price benchmarks can be found at: <http://www.icer-review.org/wp-content/uploads/2014/01/Slides-on-value-framework-for-national-webinar1.pdf>.

## References:

1. World Health Organization. Global Report on Psoriasis. 2016; [http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf). Accessed June 23, 2016.
2. Lee YW, Park EJ, Kwon IH, Kim KH, Kim KJ. Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life. *Annals of Dermatology*. 2010;22(4):389-396.
3. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. *Journal of the American Academy of Dermatology*. 2014;70(5):871-881 e871-830.
4. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. *Journal of the American Academy of Dermatology*. 1999;41(3 Pt 1):401-407.
5. Boehncke WH, Schon MP. Psoriasis. *Lancet*. 2015;386(9997):983-994.
6. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. *Journal of the American Academy of Dermatology*. 2013;69(5):729-735.
7. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Archives of Dermatological Research*. 2011;303(1):1-10.
8. Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. *The Journal of Investigative Dermatology*. 2015;135(11):2641-2648.
9. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. *JAMA Dermatology*. 2013;149(10):1180-1185.
10. Paek SY, Thompson JM, Qureshi AA, Merola JF, Husni ME. Comprehensive Assessment of the Psoriasis Patient (CAPP): A Report from the GRAPPA 2015 Annual Meeting. *The Journal of Rheumatology*. 2016;43(5):961-964.
11. Zhang W, Islam N, Ma C, Anis AH. Systematic review of cost-effectiveness analyses of treatments for psoriasis. *PharmacoEconomics*. 2015;33(4):327-340.